Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- June15 2003
- Volume 10
- Issue 11
CDs FOR BETTER YIELDS
Author(s)Michael Sheehan
Advertisement
If you're unhappy with the pint-sizedyields on your money marketaccount, bank CDs may be thesolution. To find the best CD ratesin the country, look up BauerFinancial's resources (800-388-6686; www.bauerfinancial.com). Apublisher of banking newsletters,Florida-based Bauer Financial listsCD rates for both consumer andjumbo CDs. You also get free accessto star ratings on all US banks andcredit unions. Bauer Financial'sCD ratings range from 5 stars(superior) to none. You can alsoorder any of the site's full range ofreports on banks, thrifts, and creditunions by simply clicking on thesite's "Products" area.
Articles in this issue
about 18 years ago
CLOUDY CRYSTAL BALLabout 18 years ago
TAX LAW FOR GULLIBLEabout 18 years ago
BOND YIELDS HIT LOWabout 18 years ago
RENTAL RATES RISINGabout 18 years ago
CONFESSING THEIR SINSabout 18 years ago
KEEPING YOUR BALANCEabout 18 years ago
PHARMACEUTICAL STOCKWATCHabout 18 years ago
DID YOU KNOW?about 18 years ago
KIDS & FINANCESabout 18 years ago
THE PRESIDENT PAYSAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5